Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 20;329(23):2091-2094.
doi: 10.1001/jama.2023.7683.

Short-term Adverse Events Following Immunization With Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) Vaccine for Mpox

Lucy Deng  1 , Laura K Lopez  1 , Catherine Glover  1 , Patrick Cashman  2 , Renee Reynolds  2 , Kristine Macartney  1 , Nicholas Wood  1
Affiliations

Short-term Adverse Events Following Immunization With Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) Vaccine for Mpox

Lucy Deng et al. JAMA. .
No abstract available

Plain language summary

This study uses data collected by Australia’s vaccine safety surveillance system to examine the adverse event profile of the modified vaccinia Ankara–Bavarian Nordic vaccine.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Drs Deng, Lopez, and Wood and Ms Glover reported receiving grants from the Australian Department of Health and Aged Care. Dr Macartney reported receiving grants from Australian Government Department of Health during the conduct of the study and grants from NSW Department of Health, World Health Organization, Gavi, the Australian Government Department of Foreign Affairs and Trade, and the Centers for Disease Control and Prevention outside the submitted work. No other disclosures were reported.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Australian Technical Advisory Group on Immunisation . Updated ATAGI Clinical Guidance on Vaccination Against Monkeypox (MPOX); 2022. Accessed January 5, 2023. https://www.health.gov.au/resources/publications/atagi-clinical-guidance...
    1. Deng L, Glover C, Dymock M, et al. . The short term safety of COVID-19 vaccines in Australia: AusVaxSafety active surveillance, February-August 2021. Med J Aust. 2022;217(4):195-202. doi:10.5694/mja2.51619 - DOI - PMC - PubMed
    1. Frey SE, Wald A, Edupuganti S, et al. . Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects. Vaccine. 2015;33(39):5225-5234. doi:10.1016/j.vaccine.2015.06.075 - DOI - PMC - PubMed
    1. US Food and Drug Administration . JYNNEOS: full prescribing information. Updated March 2023. Accessed January 5, 2023. https://www.fda.gov/media/131078/download
    1. Overton ET, Lawrence SJ, Wagner E, et al. . Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: a randomised, double blind, placebo controlled phase III trial. PLoS One. 2018;13(4):e0195897. doi:10.1371/journal.pone.0195897 - DOI - PMC - PubMed

Publication types

Substances